Aquestive Therapeutics Sees Stock Surge Following FDA Approval News

Updated 9/28/2025, 9:14 am ET 9/28/2025, 9:14 am ET | 6 min 6 min read

Aquestive Therapeutics Inc. stocks have been trading up by 12.17 percent amid positive sentiment and promising therapeutic advancements.

Healthcare industry expert:

Analyst sentiment – positive

Aquestive Therapeutics (AQST) occupies a challenging position in the market with significant pressure on its fundamental metrics. The company reports a negative EBIT margin of -130.8% and a gross margin of 61.1%. Despite generating $57.56 million in revenue, it registers negative profitability, underscoring the need for strategic pivots to counterbalance the declining revenue trends over three and five years, at -4.01% and -5.73% respectively. High operational costs contribute to a concerning net loss of $13.55 million in recent financials. Liquidity remains moderate with a current ratio of 3.5, and capital issues are evident with negative stockholders’ equity at -$72.59 million, reflecting a fragile financial structure.

From a technical perspective, AQST demonstrated a bullish trend with a significant breakout observed on September 25th, where the stock surged to a high of $6.25 before closing at $5.90. This breakout is supported by increased trading volume, indicating strong buying interest. The sustained upward momentum leading to a strong close at $5.90 on September 26 confirms short-term bullishness. For traders, the $5.90 level now serves as critical support, while a move past $6.25 could signal further upside potential. The recommended strategy is to enter long positions on dips towards $5.50, with a stop below $5.17, targeting an initial resistance level of $6.25.

Catalysts favoring AQST include the FDA’s decision not to require an advisory committee meeting for the Anaphylm NDA, enhancing approval prospects by their action date on January 31, 2026. The positive market response, with share price surges exceeding industry growth, bolstered by coverage upgrades from Oppenheimer, indicates growing investor confidence. LifeSci Capital’s Outperform rating and $10 price target provide additional bullish sentiment. The healthcare sector’s favorability toward innovative drug delivery systems strengthens AQST’s outlook. Given the defined resistance at $8.00 due to recent upgrades, a short-term rally is plausible. Overall, prospects appear bolstered with strategic, operational, and regulatory drivers favoring forward momentum.

Weekly Update Sep 22 – Sep 26, 2025: On Sunday, September 28, 2025 Aquestive Therapeutics Inc. stock [NASDAQ: AQST] is trending up by 12.17%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In recent trading sessions, Aquestive Therapeutics’ share price has seen a dynamic rally. The closing price climbed to $5.90 recently, enjoying a strong upward trajectory. The intraday high was $6.43; this marks a promising peak for this period. Such a rapid heavy trading momentum with increased volume strengthens the bullish sentiment surrounding the stock.

Digging into their financials, the company has experienced declining revenues over the past few years, showcasing a downturn trend with a 3-year revenue depreciation rate at -4.01%. Their high gross margin of 61.1% tempers this negative backdrop slightly. However, profitability remains a challenge, given negative margins that weigh heavily on earnings and an EBIT margin of -130.8%.

The observed quick ratio of 3.0 positions Aquestive favorably in terms of liquidity, reflecting solid capacity to handle short-term liabilities. Notably, the current ratio of 3.5 further suggests that they efficiently adapt to their ongoing financial commitments. Their cash position remains comfortably high, reaching $60.5M as of the latest report, a resource that can back its operational scalability amid FDA developments.

More Breaking News

Metrics provided highlight considerable operating losses, evidenced by a negative EBITDA that hinders current profitability. Operating Cash Flow is also under pressure, standing at -$7.91M, pointing towards an ongoing need for strategic cost management. With a focus on financial strengthening, capital expenditures are being curbed—limited to just $107,000 recently.

Conclusion

Aquestive Therapeutics stands at a promising crossroads, bolstered by their regulatory advancements with Anaphylm. The FDA’s decision to forego an advisory committee meeting is a landmark step that paves the way for strategic market entry in 2026. This clarity around approval processes has fueled significant stock price growth and heightened trader interest.

With augmented price targets and strengthened market confidence, Aquestive finds itself well-positioned for growth and innovation. While financial challenges remain, especially in terms of profitability metrics, the company’s operational liquidity and capital management reflect its capacity to navigate these hurdles. As the PDUFA date approaches, additional positive developments could further escalate stock momentum and trader sentiment. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” This wisdom is pertinent as Aquestive progresses and traders consider timing their market entries judiciously.

In summation, recent dynamics indicate a promising narrative for traders, centering around strategic growth potential and pipeline diversification. With market endorsement and favorable regulatory milestones, there’s a strong foundation for financial recovery and progression into the pharmaceutical market’s competitive terrains.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)

Stock News